Testing an immunotherapy drug for tumors with immune cell clusters
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug (called MEDI5752) for people with certain solid tumors that have a special immune feature called 'mature tertiary lymphoid structures.' The drug is designed to help your immune system fight the cancer more effectively. You may be able to join even if you haven't had immunotherapy before, or if you had it and it stopped working after a while.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that is advanced or has spread and cannot be removed with surgery.
- You can join if you have never had immunotherapy, or if you had immunotherapy that worked for at least 4 months before your cancer started growing again.
- Your tumor must have a specific type of immune cell cluster called 'mature tertiary lymphoid structures' (TLS), which will be checked with a biopsy.
- You must be 18 years or older, weigh more than 35 kg (about 77 pounds), and be in generally good health (able to do light activities).
- You must have at least one tumor that can be biopsied for research.
- You must not have had more than three lines of prior treatment for metastatic disease, and you must be willing to use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.